TBP and spinocerebellar ataxia type 17: Previously, we identified MANF as a target downregulated by TBP with polyQ expansion, and increasing MANF expression ameliorated SCA17 neuropathology in TBP-105Q knock-in (KI) mouse model [23], indicating that MANF is a potential therapeutic target for SCA17 treatment.